Why ICER’s Model Doesn’t Work for Rheumatoid Arthritis Treatments
February 24, 2017
The Institute for Clinical and Economic Review has issued a draft report concluding that targeted immune modulators, such as biologic treatments, for rheumatoid arthritis are too expensive. The conclusion could embolden health plans to limit patient access.
But does ICER’s model accurately reflect the experiences of the 1.5 million Americans with rheumatoid arthritis?Cost Value
Categorized in: Analysis